On November 23, 2017, Teng, Che-Ming; Liou, Jing-Ping; Pan, Shiow-Lin; Yang, Chia-Ron published a patent.Synthetic Route of 62163-09-1 The title of the patent was Preparation of benzohydroxamic acid and (E)-3-phenylpropenohydroxamic acid derivatives as selective histone deacetylase 6 inhibitors and use thereof. And the patent contained the following:
The hydroxamic acid compounds of formula I [R1, R2, R3, R4 = independently H, halo, cyano, amino, hydroxy, COR, CO2R, CONR’R”, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or R3 and R4, together with the C in CR3R4, form C(:O), C(:S), or C(=NH); R, R’, R” = independently H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; W = bicyclic aryl or bicyclic heteroaryl; X = CR5R6, O, S, or NR7; R5, R6, R7 = independently H, COR, CO2R, CONR’R”, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C2-5 alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Y = arylene or heteroarylene; Z = a bond, methylene, or ethylene; m, n = independently 0 or 1; wherein each of the C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C2-5 alkoxy, C1-8 alkyl, C2-5 alkenyl, C2-8 alkynyl, C1-8 alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylene, and heteroarylene are unsubstituted or substituted with halo, cyano, amino, hydroxy, nitro, sulfhydryl, C1-5 alkyl, C2-5 alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl] or pharmaceutically acceptable salts thereof are prepared The compounds I or pharmaceutically acceptable salts thereof are selective inhibitors of histone deacetylase 6 (HDAC6) over other histone deacetylases including HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, and sirtuin-1. A pharmaceutical composition containing the compound I or pharmaceutically acceptable salt thereof and a method of using the compounds I for treating a condition associated with histone deacetylase 6 such as cancer or neurodegenerative disorder are also disclosed. Thus, reductive amination of Me terephthalaldehydate with 5-aminoquinoline and NaBH(OAc)3 in the presence of AcOH at room temperature gave Me 4-[(quinolin-5-ylamino)methyl]benzoate which was condensed with hydroxylamine in the presence of NaOH in methanol at room temperature to give N-hydroxy-4-[(quinolin-5-ylamino)methyl]benzamide (II). II showed IC50 of 2.65 μM and 2.73 nM against histone deacetylase 1 (HDAC1) and histone deacetylase 6 (HDAC6), resp., compared to IC50 of 9.5 μM and 26.16 nM, resp., for tubastatin A. II showed GI50 of 3.28±0.11 μM and 5.53±0.24 nM against the proliferation of prostate cancer (PC-3) and lung (A549) cancer cell line, resp., compared to GI50 of 48.19±0.43 μM and 52.2±1.28 nM, resp., for tubastatin A. The experimental process involved the reaction of 5-Chloroquinoxaline(cas: 62163-09-1).Synthetic Route of 62163-09-1
The Article related to benzohydroxamic acid preparation selective histone deacetylase 6 inhibitor, cancer neurodegenerative disease treatment benzohydroxamic acid phenylpropenohydroxamic acid preparation, phenylpropenohydroxamic acid preparation selective histone deacetylase 6 inhibitor, hydroxyphenylacrylamide hydroxybenzamide preparation histone deacetylase 6 inhibitor and other aspects.Synthetic Route of 62163-09-1
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider